BioAge Labs (BIOA) Non-Current Debt (2023 - 2025)

BioAge Labs (BIOA) posted Non-Current Debt of $1.1 million for Q1 2025, down 57.79% sequentially from $2.5 million in Q4 2024.

BioAge Labs (BIOA) Non-Current Debt (2023 - 2025) Analysis & Trends

BioAge Labs has reported Non-Current Debt for 3 years, with the latest figure at $1.1 million in Q1 2025.

Quarterly Non-Current Debt changed N/A year-over-year to $1.1 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $1.1 million (changed N/A YoY) and the FY2024 annual result came in at $2.5 million, down 69.49% from the prior year.
Non-Current Debt declined to $1.1 million in Q1 2025 per BIOA's latest filing, from $2.5 million in the prior quarter.
Over five years, Non-Current Debt peaked at $8.2 million in Q4 2023 and troughed at $1.1 million in Q1 2025.
A 3-year average of $3.9 million and a median of $3.2 million in 2024 frame the typical range for Non-Current Debt.
The widest YoY moves for Non-Current Debt: up 69.49% in 2024, down 69.49% in 2024.
Over 3 years, Non-Current Debt stood at $8.2 million in 2023, then plunged by 69.49% to $2.5 million in 2024, then tumbled by 57.79% to $1.1 million in 2025.
According to Business Quant data, Non-Current Debt over the past three periods registered $1.1 million, $2.5 million, and $3.9 million for Q1 2025, Q4 2024, and Q3 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Haleon	43.85 Bn	42.88 Bn	-	-8.44 Bn
2	Teva Pharmaceutical Industries	43.02 Bn	39.37 Bn	2.15 Bn	12.09 Bn
3	Zoetis	31.47 Bn	29.79 Bn	1.05 Bn	9.05 Bn
4	Takeda Pharmaceutical	28.59 Bn	22.79 Bn	5.10 Bn	27.73 Bn
5	United Therapeutics	22.20 Bn	19.53 Bn	683.80 Mn	-
6	Viatris	18.76 Bn	17.87 Bn	1.46 Bn	11.61 Bn
7	Neurocrine Biosciences	15.45 Bn	15.06 Bn	935.80 Mn	-
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	3.85 Bn
9	Dr Reddys Laboratories	10.10 Bn	9.94 Bn	-	130.00 Mn
10	BioAge Labs	434.04 Mn	434.04 Mn	-14.23 Mn	-

Download Data